These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
481 related articles for article (PubMed ID: 26563374)
41. Exosomes and the MICA-NKG2D system in cancer. Clayton A; Tabi Z Blood Cells Mol Dis; 2005; 34(3):206-13. PubMed ID: 15885603 [TBL] [Abstract][Full Text] [Related]
42. MUC16 provides immune protection by inhibiting synapse formation between NK and ovarian tumor cells. Gubbels JA; Felder M; Horibata S; Belisle JA; Kapur A; Holden H; Petrie S; Migneault M; Rancourt C; Connor JP; Patankar MS Mol Cancer; 2010 Jan; 9():11. PubMed ID: 20089172 [TBL] [Abstract][Full Text] [Related]
43. Induction of NKG2D ligands and increased sensitivity of tumor cells to NK cell-mediated cytotoxicity by hematoporphyrin-based photodynamic therapy. Park MJ; Bae JH; Chung JS; Kim SH; Kang CD Immunol Invest; 2011; 40(4):367-82. PubMed ID: 21314289 [TBL] [Abstract][Full Text] [Related]
44. Reduced immune effector cell NKG2D expression and increased levels of soluble NKG2D ligands in multiple myeloma may not be causally linked. von Lilienfeld-Toal M; Frank S; Leyendecker C; Feyler S; Jarmin S; Morgan R; Glasmacher A; Märten A; Schmidt-Wolf IG; Brossart P; Cook G Cancer Immunol Immunother; 2010 Jun; 59(6):829-39. PubMed ID: 20024547 [TBL] [Abstract][Full Text] [Related]
45. Soluble ligands for the NKG2D receptor are released during HIV-1 infection and impair NKG2D expression and cytotoxicity of NK cells. Matusali G; Tchidjou HK; Pontrelli G; Bernardi S; D'Ettorre G; Vullo V; Buonomini AR; Andreoni M; Santoni A; Cerboni C; Doria M FASEB J; 2013 Jun; 27(6):2440-50. PubMed ID: 23395909 [TBL] [Abstract][Full Text] [Related]
46. Varicella-Zoster Virus and Herpes Simplex Virus 1 Differentially Modulate NKG2D Ligand Expression during Productive Infection. Campbell TM; McSharry BP; Steain M; Slobedman B; Abendroth A J Virol; 2015 Aug; 89(15):7932-43. PubMed ID: 25995251 [TBL] [Abstract][Full Text] [Related]
47. Natural killer group 2D receptor and its ligands in cancer immune escape. Duan S; Guo W; Xu Z; He Y; Liang C; Mo Y; Wang Y; Xiong F; Guo C; Li Y; Li X; Li G; Zeng Z; Xiong W; Wang F Mol Cancer; 2019 Feb; 18(1):29. PubMed ID: 30813924 [TBL] [Abstract][Full Text] [Related]
48. Inhibition of glycogen synthase kinase-3 increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: role of STAT3. Fionda C; Malgarini G; Soriani A; Zingoni A; Cecere F; Iannitto ML; Ricciardi MR; Federico V; Petrucci MT; Santoni A; Cippitelli M J Immunol; 2013 Jun; 190(12):6662-72. PubMed ID: 23686482 [TBL] [Abstract][Full Text] [Related]
49. Nitric oxide donors increase PVR/CD155 DNAM-1 ligand expression in multiple myeloma cells: role of DNA damage response activation. Fionda C; Abruzzese MP; Zingoni A; Soriani A; Ricci B; Molfetta R; Paolini R; Santoni A; Cippitelli M BMC Cancer; 2015 Jan; 15():17. PubMed ID: 25609078 [TBL] [Abstract][Full Text] [Related]
50. Decreased expression of DNAM-1 on NK cells from acute myeloid leukemia patients. Sanchez-Correa B; Gayoso I; Bergua JM; Casado JG; Morgado S; Solana R; Tarazona R Immunol Cell Biol; 2012 Jan; 90(1):109-15. PubMed ID: 21383766 [TBL] [Abstract][Full Text] [Related]
51. Up-regulation of DNAM-1 and NKp30, associated with improvement of NK cells activation after long-term culture of mononuclear cells from patients with ovarian neoplasia. da Silva RF; Petta CA; Derchain SF; Alici E; Guimarães F Hum Immunol; 2014 Aug; 75(8):777-84. PubMed ID: 24882570 [TBL] [Abstract][Full Text] [Related]
52. Exosomal transfer of HCC-derived miR-17-5p downregulates NK cell function by targeting RUNX1-NKG2D axis. Zhou Z; Li T; Li J; Lin W; Zheng Q Int Immunopharmacol; 2024 Jul; 136():112361. PubMed ID: 38820961 [TBL] [Abstract][Full Text] [Related]
53. Natural Killer Cell Phenotype and Functionality Affected by Exposure to Extracellular Survivin and Lymphoma-Derived Exosomes. Ferguson Bennit HR; Gonda A; Kabagwira J; Oppegard L; Chi D; Licero Campbell J; De Leon M; Wall NR Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33513976 [TBL] [Abstract][Full Text] [Related]
54. Endometriotic Tissue-derived Exosomes Downregulate NKG2D-mediated Cytotoxicity and Promote Apoptosis: Mechanisms for Survival of Ectopic Endometrial Tissue in Endometriosis. Björk E; Israelsson P; Nagaev I; Nagaeva O; Lundin E; Ottander U; Mincheva-Nilsson L J Immunol; 2024 Sep; 213(5):567-576. PubMed ID: 38984872 [TBL] [Abstract][Full Text] [Related]
55. Primary human tumor cells expressing CD155 impair tumor targeting by down-regulating DNAM-1 on NK cells. Carlsten M; Norell H; Bryceson YT; Poschke I; Schedvins K; Ljunggren HG; Kiessling R; Malmberg KJ J Immunol; 2009 Oct; 183(8):4921-30. PubMed ID: 19801517 [TBL] [Abstract][Full Text] [Related]
56. Shedding of endogenous MHC class I-related chain molecules A and B from different human tumor entities: heterogeneous involvement of the "a disintegrin and metalloproteases" 10 and 17. Chitadze G; Lettau M; Bhat J; Wesch D; Steinle A; Fürst D; Mytilineos J; Kalthoff H; Janssen O; Oberg HH; Kabelitz D Int J Cancer; 2013 Oct; 133(7):1557-66. PubMed ID: 23526433 [TBL] [Abstract][Full Text] [Related]
57. Macrophages derived exosomes deliver miR-223 to epithelial ovarian cancer cells to elicit a chemoresistant phenotype. Zhu X; Shen H; Yin X; Yang M; Wei H; Chen Q; Feng F; Liu Y; Xu W; Li Y J Exp Clin Cancer Res; 2019 Feb; 38(1):81. PubMed ID: 30770776 [TBL] [Abstract][Full Text] [Related]
58. Induction of NKG2D ligands and subsequent enhancement of NK cell-mediated lysis of cancer cells by arsenic trioxide. Kim JY; Bae JH; Lee SH; Lee EY; Chung BS; Kim SH; Kang CD J Immunother; 2008 Jun; 31(5):475-86. PubMed ID: 18463537 [TBL] [Abstract][Full Text] [Related]
59. Exosomal miR-99a-5p is elevated in sera of ovarian cancer patients and promotes cancer cell invasion by increasing fibronectin and vitronectin expression in neighboring peritoneal mesothelial cells. Yoshimura A; Sawada K; Nakamura K; Kinose Y; Nakatsuka E; Kobayashi M; Miyamoto M; Ishida K; Matsumoto Y; Kodama M; Hashimoto K; Mabuchi S; Kimura T BMC Cancer; 2018 Nov; 18(1):1065. PubMed ID: 30396333 [TBL] [Abstract][Full Text] [Related]